NewsPeople

Glenmark appoints Dipankar Bhattacharjee to its Board of Directors

Bhattacharjee was previously President & CEO – Global Generic Medicines of Teva Pharmaceutical Industries Ltd and has over thirty years of global pharmaceutical experience

Mumbai, India; August 17, 2020: Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the appointment of Mr. Dipankar Bhattacharjee as Independent Non-Executive Director on the Board of the organization for a period of five years with effect from 14th August, 2020.

Mr. Bhattacharjee comes with over 30 years of global experience in leading Generics, Specialty and OTC Pharma, Medical Devices, and FMCG businesses. He has led high performing teams to develop and execute business strategies across all stages of business cycles, driving growth and value through commercial innovation and focused R&D investments.

THIS CAN BE YOUR ADVERTISEMENT

In his previous role, Mr. Bhattacharjee held various senior leadership positions at Teva Pharmaceutical Industries, including President & CEO – Global Generics Medicines, Officer and Member Teva Executive Committee (TEC), and Co-chair in JVs with P&G and Takeda Pharmaceuticals. With strong orientation towards stakeholders including investors, customers and consumers, and deep understanding of payers and regulators, he has consistently delivered short term and long term results across multiple geographies and business environments.

Before Teva, Mr. Bhattacharjee worked with leading global organizations such as Bausch & Lomb, Bank of America and Nestle. He holds a Master’s degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai, and a Bachelor’s degree in Economics from St. Stephen’s College, University of Delhi.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Related Articles

Leave a Reply

Back to top button
Close
Close